Minerva Neurosciences (NERV) Change in Account Payables (2014 - 2026)
Minerva Neurosciences (NERV) posted Change in Account Payables of $1.5 million for Q1 2026, up 632.31% on a QoQ basis from -$275228.0 in Q4 2025, and up 251.37% year-over-year from $416964.4 in Q1 2025.
Minerva Neurosciences (NERV) Change in Account Payables (2014 - 2026) Analysis & Trends
Minerva Neurosciences' Change in Account Payables history runs 13 years deep, the most recent figure standing at $1.5 million for Q1 2026.
- Quarterly Change in Account Payables rose 251.37% year-over-year to $1.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.4 million (up 272.69% YoY) and the FY2025 annual result came in at -$1.1 million, down 436.27% from the prior year.
- Change in Account Payables was $1.5 million for Q1 2026 at Minerva Neurosciences, up from -$275228.0 in the prior quarter.
- Across five years, Change in Account Payables topped out at $1.5 million in Q1 2026 and bottomed at -$986841.0 in Q3 2022.
- A 5-year average of $9452.4 and a median of -$72739.0 in 2025 frame the typical range for Change in Account Payables.
- Annual changes were most pronounced in 2024 — Change in Account Payables sank 4165.22% — and 2026, when it soared 251.37%.
- Minerva Neurosciences' Change in Account Payables stood at $436779.0 in 2022, then decreased by 6.07% to $410250.0 in 2023, then jumped by 157.08% to $1.1 million in 2024, then sank by 126.1% to -$275228.0 in 2025, then surged by 632.31% to $1.5 million in 2026.
- Business Quant data shows NERV's Change in Account Payables at $1.5 million in Q1 2026, -$275228.0 in Q4 2025, and -$72739.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -42.19 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.52 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 35.60 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 16.86 Mn |
| 10 | Minerva Neurosciences | 195.10 Mn | 195.10 Mn | - | 1.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.47 Mn |
| Mar 31, 2026 | 1.47 Mn |
| Dec 31, 2025 | -275,228.00 |
| Dec 31, 2025 | -275,228.00 |
| Sep 30, 2025 | -72,739.00 |
| Sep 30, 2025 | -72,739.00 |
| Jun 30, 2025 | 256,853.00 |
| Jun 30, 2025 | 256,853.00 |
| Mar 31, 2025 | -967,898.00 |
| Mar 31, 2025 | -967,898.00 |
| Dec 31, 2024 | 1.05 Mn |
| Dec 31, 2024 | 1.05 Mn |
| Sep 30, 2024 | -275,153.00 |
| Sep 30, 2024 | -275,153.00 |
| Jun 30, 2024 | -607,223.00 |
| Jun 30, 2024 | -607,223.00 |
| Mar 31, 2024 | -369,752.00 |
| Mar 31, 2024 | -369,752.00 |
| Dec 31, 2023 | 410,250.00 |
| Dec 31, 2023 | 410,250.00 |